Molecular Templates Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Molecular Templates han disminuido a una tasa media anual de -12.9%, mientras que en la industria Biotechs los beneficios crecieron en un 17.7% anualmente. Los ingresos han ido creciendo a una tasa media de 25.4% al año.

Información clave

-12.9%

Tasa de crecimiento de los beneficios

-0.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	25.4%
Rentabilidad financiera	n/a
Margen neto	-92.8%
Última actualización de beneficios	30 Jun 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Molecular Templates. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:NZW Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 23	50	-47	23
31 Mar 23	48	-60	24
31 Dec 22	20	-93	26
30 Sep 22	35	-81	27
30 Jun 22	33	-87	31
31 Mar 22	44	-78	33
31 Dec 21	39	-83	34
30 Sep 21	24	-101	33
30 Jun 21	26	-94	32
31 Mar 21	18	-110	29
31 Dec 20	19	-105	27
30 Sep 20	22	-92	26
30 Jun 20	21	-107	23
31 Mar 20	19	-85	21
31 Dec 19	22	-69	20
30 Sep 19	21	-60	18
30 Jun 19	24	-27	17
31 Mar 19	20	-28	16
31 Dec 18	13	-30	14
30 Sep 18	9	-31	14
30 Jun 18	3	-36	12
31 Mar 18	2	-31	11
31 Dec 17	3	-24	10
30 Sep 17	3	-20	8
30 Jun 17	2	-13	6
31 Mar 17	3	-11	5
31 Dec 16	2	-13	4
31 Dec 15	1	-7	3

Ingresos de calidad: NZW actualmente no es rentable.

Margen de beneficios creciente: NZW actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: NZW no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 12.9% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de NZW en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: NZW no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: El pasivo de NZW supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Molecular Templates Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.43 loss in 2Q 2022)

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.43 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.38 loss in 1Q 2022)

Full year 2022 earnings released: US$1.65 loss per share (vs US$1.50 loss in FY 2021)

Third quarter 2022 earnings released: US$0.44 loss per share (vs US$0.54 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.28 loss in 2Q 2021)

Recent updates

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting

Molecular Templates, Inc. Announces Board Changes

Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc. Announces the Appointment of Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

New major risk - Revenue and earnings growth

Molecular Templates Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.43 loss in 2Q 2022)

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.43 loss in 2Q 2022)

Molecular Templates, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

Molecular Templates, Inc. announced that it expects to receive $40.044 million in funding from BVF Partners L.P., Adage Capital Management, L.P., Bellevue Asset Management AG

New major risk - Financial position

Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.38 loss in 1Q 2022)

Full year 2022 earnings released: US$1.65 loss per share (vs US$1.50 loss in FY 2021)

Insufficient new directors

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Molecular Templates, Inc. Announces CFO Changes

Third quarter 2022 earnings released: US$0.44 loss per share (vs US$0.54 loss in 3Q 2021)

Molecular Templates Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.28 loss in 2Q 2021)

Molecular Templates, Inc.(NasdaqGS:MTEM) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.38 loss per share (vs US$0.51 loss in 1Q 2021)

Full year 2021 earnings released: US$1.50 loss per share (vs US$2.20 loss in FY 2020)

Molecular Templates, Inc. Announces Management Appointments

Molecular Templates, Inc. Announces Management Appointments

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.47 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.28 loss per share (vs US$0.68 loss in 2Q 2020)

CFO, Treasurer & Secretary Adam Cutler has left the company

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.51 loss per share (vs US$0.48 loss in 1Q 2020)

Molecular Templates, Inc. Expects to Generate Clinical Data

Full year 2020 earnings released: US$2.20 loss per share (vs US$1.84 loss in FY 2019)

Molecular Templates, Inc. has completed a Follow-on Equity Offering in the amount of $75.9 million.

Molecular Templates, Inc. Establishes Multi-Target Collaboration with Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer

New 90-day high: €12.40

New 90-day high: €9.35

Molecular Templates, Inc. Announces Fda Acceptance of Ind Application for Mt-6402, A Pd-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

New 90-day low: €6.65

Revenue misses expectations

Third quarter 2020 earnings released: US$0.47 loss per share

Molecular Templates, Inc. Provides Update on Its Clinical Pipeline

New 90-day low: €7.25

New 90-day low - €8.75

First half earnings released

Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell 2000 Value Index

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta